FFAR4 and obesity disorder: For GPR120, however, the binding of omega-3 polyunsaturated fatty acids (ω3-FAs) and receptor activation can reduce inflammation of adipose tissue and protect against insulin resistance.93 The receptor’s coupling with Gq/11 subsequently stimulates the PI3K/Akt pathway, resulting in the uptake of glucose in adipocytes.94 As GLP-1R agonist liraglutide takes the lead in FDA-approved drugs treating type 2 diabetes and obesity,95 drug development of more endocrine-related targets such as GPR35, GPR40, GPR41, GPR43, GPR81, and GPR119 are supposed to come into our view.